As the cell and gene therapy market has exponentially grown in recent years — with some reports predicting it will reach $24.4 billion with 54 to 74 approvals by 2030 — many manufacturers are learning the hard way just how complex it can be to launch these products, and that’s after already making it through the arduous development and clinical trial process. Among the many things to navigate, a manufacturer must put together a medical communications plan for patients and healthcare providers that can help crystalize the nuances of cell and gene therapies.
Read our contributed article on CellandGene.com to learn more.